News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Osmetech Plc (OMH)'s Exclusive Warfarin CYP4F2 Biomarker Included in Leading Warfarindosing.org Algorithm


6/8/2009 12:12:43 PM

PASADENA, Calif.--(BUSINESS WIRE)--Osmetech plc (LSE:OMH), the international molecular diagnostics company, announces that its exclusive CYP450 4F2 biomarker has been included on the leading warfarin dosing website, www.warfarindosing.org, a free Web site to aid doctors and other clinicians in warfarin therapy by estimating the therapeutic dose in patients new to warfarin or within first 4 INRs.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES